The report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. Read the full story

Genmab, a top big biotech company, headquartered in Denmark is one of the leaders today in the human antibody therapeutics market for cancer treatment. Read the full story

MorphoSys, a leader in antibody drug discovery, has emerged as a top 50 big biotech company with its product pipeline and partnering strategy. Read the full story

Genmab is an internationally recognised biotechnology company developing human antibody therapeutics primarily for cancer. Read the full story

Morphosys is a leading biotechnology developing therapeutic antibodies for a range of different indications. Read the full story

Seattle Genetics is a biotech company developing and commercializing antibody-based therapeutics to improve the lives of people living with cancer. Read the full story

Seattle Genetics, a successful big biotech industry headquartered in Seattle, focuses its effort on advancing antibody drug conjugate technology targeted toward cancer treatment. Read the full story

Mersana Therapeutics and Merck KGaA announced an biotech partnering to collaboratively develop next-generation antibody-drug conjugates (ADCs) for $792 million. Read the full story

Antibodies are the subject of numerous partnering deals every year, here we provide a review of recent partnering trends activity. Read the full story

PDL Biopharma based in Nevada manages patents associated with its humanized monoclonal antibodies technology. Read the full story